STOCK TITAN
  1. Home
  2. Sec-filings
  3. AAPG
  4. [Form 3/A] ASCENTAGE PHARMA GROUP INTERNATIONAL Amended Initial Statement of Beneficial Ownership

Ascentage Pharma (AAPG) director updates option and RSU holdings

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3/A

Rhea-AI Filing Summary

ASCENTAGE PHARMA GROUP INTERNATIONAL director Marc E. Lippman filed an amended Form 3 updating his equity holdings. He now reports stock options covering 17,965 Ordinary Shares at an exercise price of 8.1400 per share expiring on November 26, 2035, 27,965 underlying Ordinary Shares from restricted share units, and 21,174 Ordinary Shares held directly.

The footnotes explain that the options vest in twelve equal monthly tranches starting on November 26, 2025, while the restricted stock units vest in four equal annual increments on November 26 of 2026 through 2029. The filing also states that the number of share options and/or vesting were inadvertently reported incorrectly in the original submission and are corrected here.

Positive

  • None.

Negative

  • None.
Insider LIPPMAN MARC E
Role Director
Type Security Shares Price Value
holding Options -- -- --
holding Restricted share units -- -- --
holding Ordinary Shares -- -- --
Holdings After Transaction: Options — 17,965 shares (Direct); Restricted share units — 27,965 shares (Direct); Ordinary Shares — 21,174 shares (Direct)
Footnotes (1)
  1. The stock options vest in twelve (12) tranches equally on the 26th of the month starting November 26, 2025. The exercise price for the stock options is in HKD, and the exercise price included in the table represents conversion to USD based on the exchange rate on the date of grant. Each restricted stock unit (RSUs) represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029. The number of Share Options and/or vesting were inadvertently incorrectly reported in the original submission.
Understanding Insider Trading Forms →
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
LIPPMAN MARC E
(Last)(First)(Middle)
700 KING FARM BLVD
STE 510
(Street)
ROCKVILLE MARYLAND 20850
(City)(State)(Zip)
UNITED STATES
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026		3. Issuer Name and Ticker or Trading Symbol
ASCENTAGE PHARMA GROUP INTERNATIONAL [ AAPG ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
03/19/2026
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares21,174D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Options (1)11/26/2035Ordinary Shares17,965(4)$8.14(2)D
Restricted share units (3) (3)Ordinary Shares27,965(4)$0D
Explanation of Responses:
1. The stock options vest in twelve (12) tranches equally on the 26th of the month starting November 26, 2025.
2. The exercise price for the stock options is in HKD, and the exercise price included in the table represents conversion to USD based on the exchange rate on the date of grant.
3. Each restricted stock unit (RSUs) represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029.
4. The number of Share Options and/or vesting were inadvertently incorrectly reported in the original submission.
Remarks:
This form is filed using a special power of attorney.
Thomas J. Knapp03/23/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What does the amended Form 3 for ASCENTAGE PHARMA (AAPG) report for Marc E. Lippman?

The amended Form 3 updates Marc E. Lippman’s reported equity stake in Ascentage Pharma. It details his stock options, restricted share units, and directly held Ordinary Shares, correcting previously misstated option counts and vesting terms disclosed in the original filing.

How many stock options does Marc E. Lippman report in AAPG after this amendment?

Marc E. Lippman reports options over 17,965 Ordinary Shares of Ascentage Pharma. These options have an exercise price of 8.1400 per share and expire on November 26, 2035, providing long-dated potential ownership if exercised under the specified vesting schedule.

What restricted share unit (RSU) holdings are disclosed for Marc E. Lippman in AAPG?

The filing shows restricted share units representing 27,965 underlying Ordinary Shares of Ascentage Pharma. Each RSU converts into one share upon vesting, with vesting occurring in four equal increments on November 26 of 2026, 2027, 2028, and 2029.

How many Ordinary Shares of AAPG does Marc E. Lippman hold directly after the amendment?

Marc E. Lippman reports direct ownership of 21,174 Ordinary Shares of Ascentage Pharma. This figure reflects his current reported share position and sits alongside his option and RSU awards disclosed in the amended Form 3 filing.

What vesting schedule applies to Marc E. Lippman’s AAPG stock options?

The stock options vest in twelve equal tranches on the 26th of each month. Vesting begins on November 26, 2025, spreading the vesting over one year, which gradually increases his exercisable options over that period.

Why did Ascentage Pharma file an amended Form 3 (3/A) for AAPG?

The amendment corrects earlier reporting errors regarding Marc E. Lippman’s share options and vesting. The footnotes state that the number of share options and/or vesting were inadvertently reported incorrectly in the original submission and are now revised.